Medicine and Dentistry
Breast Cancer
100%
Patient
65%
Neoplasm
30%
Therapeutic Procedure
26%
Biological Marker
22%
Analysis
21%
Tamoxifen
19%
Estrogen Receptor
16%
Follow up
14%
Breast
13%
Cyclophosphamide
12%
Fluorouracil
12%
Gamma Urogastrone
12%
Prognosis
12%
Malignant Neoplasm
11%
Protein Tyrosine Kinase
11%
Recurrent Disease
11%
Hormone Therapy
11%
Hazard Ratio
10%
Epirubicin
10%
Survival
10%
Inpatient
9%
Methotrexate
9%
Combination Therapy
9%
Recurrence Free Survival
9%
Protein
8%
Chemotherapy
8%
Association
8%
Surgery
8%
Exemestane
7%
Radiation Therapy
7%
Breast Carcinoma
7%
Specimen
7%
Epidermal Growth Factor Receptor 2
7%
Clinical Trial
7%
Immunohistochemistry
7%
Tissues
7%
Pathology
7%
Cellular Infiltration
6%
Anthracycline
6%
Epidermal Growth Factor Receptor
6%
Predictor
6%
Paraffin
6%
Cancer Therapy
6%
Overall Survival
5%
Ras
5%
Tissue Microarray
5%
Learning
5%
Breast Tumor
5%
Epidermal Growth Factor Receptor
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
66%
Biological Marker
20%
Protein Tyrosine Kinase
15%
Malignant Neoplasm
14%
Gamma Urogastrone
12%
Protein
12%
Neoplasm
11%
Tamoxifen
11%
Anthracycline
11%
Chemotherapy
10%
Epidermal Growth Factor Receptor 2
9%
Epirubicin
9%
Methotrexate
9%
Cyclophosphamide
9%
Fluorouracil
9%
Aromatase Inhibitor
6%
Estrogen Receptor
6%
Enalapril Maleate
6%
Cancer Chemotherapy
5%
Everolimus
5%
Mammalian Target of Rapamycin Inhibitor
5%
Docetaxel
5%
Epidermal Growth Factor Receptor
5%
Exemestane
5%
Biochemistry, Genetics and Molecular Biology
Anthracycline
25%
Epidermal Growth Factor Receptor
14%
Protein
14%
Estrogen Receptor
12%
Receptor Tyrosine Kinase
11%
Sample
11%
Fluorescence in Situ Hybridization
10%
Clinical Trial
10%
Mammalian Target of Rapamycin
10%
Epirubicin
10%
Electric Potential
9%
in Situ Hybridization
9%
Kinase
9%
Association
9%
Protein-Tyrosine Kinase
8%
Nested Gene
8%
Overall Survival
8%
Gene Expression
7%
Cyclophosphamide
7%
Fluorouracil
7%
TOP2A
7%
Survival
6%
Gene Signature
5%
Cancer Survival
5%
Cell Infiltration
5%
RNA
5%
Development
5%